The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
← catalyst calendarNCT07211126 · readout ≤ 499 d
Sponsored by Tandem Diabetes Care, Inc. (industry) · TNDM — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
350estimated
Sites
21
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-03 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 1
Intervention
- Device: t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)
Primary outcomes
what the primary-completion date above is the date OFRate of diabetic ketoacidosis (DKA).
measured 12 months
Rate of severe hypoglycemia (SH)
measured 12 months
Permalink · TNDM's whole pipeline · Catalyst calendar · Every registered study · What changed